GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » E10

Alnylam Pharmaceuticals (LTS:0HD2) E10 : $-7.03 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-7.03 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -13.90% per year. During the past 5 years, the average E10 Growth Rate was -16.30% per year. During the past 10 years, the average E10 Growth Rate was -14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alnylam Pharmaceuticals was 30.10% per year. The lowest was -21.40% per year. And the median was -17.40% per year.

As of today (2024-05-21), Alnylam Pharmaceuticals's current stock price is $149.05. Alnylam Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-7.03. Alnylam Pharmaceuticals's Shiller PE Ratio of today is .


Alnylam Pharmaceuticals E10 Historical Data

The historical data trend for Alnylam Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals E10 Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.41 -5.05 -6.85 -6.70 -7.37

Alnylam Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.07 -7.63 -7.29 -7.37 -7.03

Competitive Comparison of Alnylam Pharmaceuticals's E10

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Shiller PE Ratio falls into.



Alnylam Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alnylam Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.52/131.7762*131.7762
=-0.520

Current CPI (Mar. 2024) = 131.7762.

Alnylam Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.580 100.560 -0.760
201409 -0.580 100.428 -0.761
201412 -0.280 99.070 -0.372
201503 -0.620 99.621 -0.820
201506 -0.850 100.684 -1.112
201509 -0.910 100.392 -1.194
201512 -1.070 99.792 -1.413
201603 -1.210 100.470 -1.587
201606 -1.050 101.688 -1.361
201609 -1.210 101.861 -1.565
201612 -1.320 101.863 -1.708
201703 -1.250 102.862 -1.601
201706 -1.340 103.349 -1.709
201709 -1.340 104.136 -1.696
201712 -1.480 104.011 -1.875
201803 -1.410 105.290 -1.765
201806 -1.630 106.317 -2.020
201809 -2.430 106.507 -3.007
201812 -2.090 105.998 -2.598
201903 -1.730 107.251 -2.126
201906 -2.020 108.070 -2.463
201909 -1.920 108.329 -2.336
201912 -2.470 108.420 -3.002
202003 -1.620 108.902 -1.960
202006 -1.560 108.767 -1.890
202009 -2.180 109.815 -2.616
202012 -2.090 109.897 -2.506
202103 -1.710 111.754 -2.016
202106 -1.610 114.631 -1.851
202109 -1.720 115.734 -1.958
202112 -2.160 117.630 -2.420
202203 -2.000 121.301 -2.173
202206 -2.290 125.017 -2.414
202209 -3.320 125.227 -3.494
202212 -1.680 125.222 -1.768
202303 -1.400 127.348 -1.449
202306 -2.210 128.729 -2.262
202309 1.150 129.860 1.167
202312 -1.100 129.419 -1.120
202403 -0.520 131.776 -0.520

Add all the adjusted EPS together and divide 10 will get our e10.


Alnylam Pharmaceuticals  (LTS:0HD2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alnylam Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (LTS:0HD2) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (LTS:0HD2) Headlines

No Headlines